Apr 23, 2025, 20:29
Tanja Obradovic: Just announced – Trodelvy in combination with Keytruda
Tanja Obradovic, Oncology Medical Strategy Advisor at Mercurial AI, shared on LinkedIn:
“Just announced – Trodelvy (sacituzumab govitecan-hziy, made by Gilead Sciences) in combination with Keytruda (pembrolizumab, by Merck) significantly improved progression-free survival (PFS) compared to Keytruda and chemotherapy in patients with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC) whose tumors express PD-L1 (CPS ≥ 10).
Results are from ASCENT-04/KEYNOTE-D19 trial, a first phase 3 study for combination of TROP2-targeting antibody-drug conjugate (ADC) Trodelvy and PD-1 inhibitor Keytruda. ‘
The study enrolled mTNBC patients with a PD-L1 combined positive score (CPS) of 10 or more, matching Keytruda’s label in first-line mTNBC (approved by FDA in 2020) Trodelvy is already approved by FDA but as a third-line treatment for mTNBC (in 2020) and with this result it is moving toward first line. Details on magnitude of PFS benefit are pending and OS results are not mature but certainly great news for mTNBC patients.”
More posts by Tanja Obradovic on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Apr 23, 2025, 20:29
Apr 23, 2025, 19:57
Apr 23, 2025, 17:10
Apr 23, 2025, 16:51